A Phase III Multicenter Randomized Study of the Biological and Clinical Efficacy of Subcutaneous Recombinant, Human Interleukin-2 in HIV-Infected Patients With Low CD4+ Counts Under Active Antiretroviral Therapy (SILCAAT Amendment 4).

Trial Profile

A Phase III Multicenter Randomized Study of the Biological and Clinical Efficacy of Subcutaneous Recombinant, Human Interleukin-2 in HIV-Infected Patients With Low CD4+ Counts Under Active Antiretroviral Therapy (SILCAAT Amendment 4).

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Aug 2011

At a glance

  • Drugs Aldesleukin; Antiretrovirals
  • Indications HIV infections; HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms SILCAAT
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 10 Dec 2010 Additional lead trial centre, investigator and trial location (USA) identified as reported by ClinicalTrials.gov.
    • 10 Dec 2010 Additional lead trial centre, investigator and trial location (USA) identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top